Difference between revisions of "Alectinib (Alecensa)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "http://www.gene.com/" to "https://www.gene.com/") |
||
| (19 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Tyrosine kinase inhibitor; inhibits anaplastic lymphoma kinase (ALK). Alectinib and its metabolite M4 inhibit ALK phosphorylation and ALK-mediated activation of the downstream signaling proteins STAT3 and AKT, which results in decreased growth of tumor cells which have ALK fusions, amplifications, or activating mutations.<ref name=insert>[ | + | Class/mechanism: Tyrosine kinase inhibitor; inhibits anaplastic lymphoma kinase (ALK). Alectinib and its metabolite M4 inhibit ALK phosphorylation and ALK-mediated activation of the downstream signaling proteins STAT3 and AKT, which results in decreased growth of tumor cells which have ALK fusions, amplifications, or activating mutations.<ref name=insert>[https://www.gene.com/download/pdf/alecensa_prescribing.pdf Alectinib (Alecensa) package insert]</ref><ref>[[:File:Alectinib.pdf|Alectinib (Alecensa) package insert (locally hosted backup)]]</ref><ref>[http://alecensa.com/ Alecensa manufacturer's website]</ref><ref>[https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=733572 Alectinib entry at the NCI Drug Dictionary]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.<ref name="insert"></ref> |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| + | *[[Anaplastic large cell lymphoma]] | ||
*[[Non-small_cell_lung_cancer,_ALK-positive|ALK+ non-small cell lung cancer]] | *[[Non-small_cell_lung_cancer,_ALK-positive|ALK+ non-small cell lung cancer]] | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[ | + | *[https://www.gene.com/download/pdf/alecensa_prescribing.pdf Alectinib (Alecensa) package insert]<ref name="insert"></ref> |
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *12 | + | *2015-12-11: Granted accelerated FDA approval for the treatment of patients with [[Biomarkers#ALK|anaplastic lymphoma kinase (ALK)]]-[[Biomarkers#Rearrangement|positive]] [[Contexts#Metastatic|metastatic]] [[Non-small_cell_lung_cancer|non-small cell lung cancer (NSCLC)]] who have progressed on or are intolerant to [[Crizotinib (Xalkori)|crizotinib]]. ''(Based on NP28761 and NP28673)'' |
| − | *11 | + | *2017-11-06: Granted regular FDA approval for treatment of patients with [[Biomarkers#ALK|anaplastic lymphoma kinase (ALK)]]-[[Biomarkers#Rearrangement|positive]] [[Contexts#Metastatic|metastatic]] [[Non-small_cell_lung_cancer|non-small cell lung cancer (NSCLC)]], as detected by an FDA-approved test. ''(Converted to regular approval; prior crizotinib exposure requirement removed; based on ALEX)'' |
| + | *2024-04-18: Approved for adjuvant treatment following tumor resection in patients with anaplastic lymphoma kinase (ALK)-positive [[Non-small_cell_lung_cancer|non-small cell lung cancer (NSCLC)]], as detected by an FDA-approved test. ''(Based on ALINA)'' | ||
| + | ==History of changes in EMA indication== | ||
| + | *2017-02-16: Initial marketing authorization as Alecensa as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced [[non-small cell lung cancer|non-small cell lung cancer (NSCLC)]] previously treated with crizotinib. | ||
| + | *2017-12-18: Extension of Indication for Alecensa (alectinib) to first line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced [[non-small cell lung cancer|non-small cell lung cancer (NSCLC)]]. ''(Prior treatment criteria removed)'' | ||
| + | |||
| + | ==History of changes in Health Canada indication== | ||
| + | *2016-09-28: Initial notice of compliance with conditions as a monotherapy for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, locally advanced (not amenable to curative therapy) or metastatic [[non-small cell lung cancer|non-small cell lung cancer (NSCLC)]] who have progressed on or are intolerant to crizotinib. | ||
| + | **2018-09-26: Conditions were met for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, locally advanced (not amenable to curative therapy) or metastatic [[non-small cell lung cancer|non-small cell lung cancer (NSCLC)]] who have progressed on or are intolerant to crizotinib. | ||
| + | *2018-06-11: New indication for the first-line treatment of patients with anaplastic lymphoma kinase-positive, locally advanced (not amenable to curative therapy) or metastatic [[non-small cell lung cancer]]. | ||
| + | ==History of changes in PMDA indication== | ||
| + | *2014-07-04: Initial approval for the treatment of unresectable advanced/relapsed ALK fusion gene-positive [[non-small cell lung cancer]]. | ||
| + | *2020-02-21: New indication and a new dosage for the treatment of relapsed or refractory ALK fusion gene-positive [[anaplastic large cell lymphoma]]. | ||
==Also known as== | ==Also known as== | ||
| − | *'''Code names:''' | + | *'''Code names:''' AF-802, CH-5424802, RG-7853, RO-5424802, UNII-LIJ4CT1Z3Y |
| − | *'''Brand names:''' Alecensa, Alecinix, Alecnib | + | *'''Brand names:''' Alecensa, Alecensaro, Alecinix, Alecnib |
==References== | ==References== | ||
| Line 26: | Line 39: | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
[[Category:Mutation-specific medications]] | [[Category:Mutation-specific medications]] | ||
| − | |||
[[Category:ALK inhibitors]] | [[Category:ALK inhibitors]] | ||
| + | [[Category:Anaplastic large cell lymphoma medications]] | ||
[[Category:Non-small cell lung cancer medications]] | [[Category:Non-small cell lung cancer medications]] | ||
[[Category:FDA approved in 2015]] | [[Category:FDA approved in 2015]] | ||
| + | [[Category:Health Canada approved in 2016]] | ||
| + | [[Category:EMA approved in 2017]] | ||
| + | [[Category:PMDA approved in 2014]] | ||
Latest revision as of 00:49, 1 July 2024
General information
Class/mechanism: Tyrosine kinase inhibitor; inhibits anaplastic lymphoma kinase (ALK). Alectinib and its metabolite M4 inhibit ALK phosphorylation and ALK-mediated activation of the downstream signaling proteins STAT3 and AKT, which results in decreased growth of tumor cells which have ALK fusions, amplifications, or activating mutations.[1][2][3][4]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 2015-12-11: Granted accelerated FDA approval for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. (Based on NP28761 and NP28673)
- 2017-11-06: Granted regular FDA approval for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Converted to regular approval; prior crizotinib exposure requirement removed; based on ALEX)
- 2024-04-18: Approved for adjuvant treatment following tumor resection in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Based on ALINA)
History of changes in EMA indication
- 2017-02-16: Initial marketing authorization as Alecensa as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.
- 2017-12-18: Extension of Indication for Alecensa (alectinib) to first line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). (Prior treatment criteria removed)
History of changes in Health Canada indication
- 2016-09-28: Initial notice of compliance with conditions as a monotherapy for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.
- 2018-09-26: Conditions were met for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.
- 2018-06-11: New indication for the first-line treatment of patients with anaplastic lymphoma kinase-positive, locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer.
History of changes in PMDA indication
- 2014-07-04: Initial approval for the treatment of unresectable advanced/relapsed ALK fusion gene-positive non-small cell lung cancer.
- 2020-02-21: New indication and a new dosage for the treatment of relapsed or refractory ALK fusion gene-positive anaplastic large cell lymphoma.
Also known as
- Code names: AF-802, CH-5424802, RG-7853, RO-5424802, UNII-LIJ4CT1Z3Y
- Brand names: Alecensa, Alecensaro, Alecinix, Alecnib